Table 1.
Baseline patient, tumor, and treatment characteristics of all patients
| Characteristics | Training Group | Testing Group | p-value |
|---|---|---|---|
| NO. of Cases | 572 | 142 | |
| Patient Characteristics | |||
| Age, year | 0.809 | ||
| Median (Range) | 73.5 (46.7-89.8) | 73.5 (48.4-91.8) | |
| Gender | 0.548 | ||
| Male | 286 (50.0%) | 67 (47.2%) | |
| Female | 286 (50.0%) | 75 (52.8%) | |
| ECOG score | 0.910 | ||
| 0 | 44 (7.7%) | 11 (7.7%) | |
| 1 | 425 (74.3%) | 109 (76.8%) | |
| 2 | 95 (16.6%) | 20 (14.1%) | |
| 3 | 8 (1.4%) | 2 (1.4%) | |
| CCI (continuous) | 0.103 | ||
| Median (Range) | 3 (2-12) | 3 (2-8) | |
| CCI (categorical) | 0.520 | ||
| 0-2 | 177 (30.9%) | 40 (28.2%) | |
| ≥3 | 395 (69.1%) | 102 (71.8%) | |
| FEV1,% of predicted | 0.764 | ||
| Median (Range) | 65.0 (11-148) | 65.0 (19-148) | |
| DLCO,% of predicted | 0.737 | ||
| Median (Range) | 58.0 (14-136) | 59.5 (18-131) | |
| NLR before SABR | 0.730 | ||
| Median (Range) | 2.77 (0.03-25.36) | 2.74 (0.39-14.04) | |
| PLR before SABR | 0.955 | ||
| Median (Range) | 140.16 (0.92-944.44) | 145.7 (6.49-449.00) | |
| SII before SABR | 0.686 | ||
| Median (Range) | 621.58 (1.98-6005.51) | 616.96 (26.09-3931.45) | |
| Tumor Characteristics | |||
| Tumor size, cm | 0.905 | ||
| Median (Range) | 2.0 (0.5-7.0) | 2.0 (0.5-6.0) | |
| Tumor Histology | 0.620 | ||
| Non-SCC | 365 (63.8%) | 96 (67.6%) | |
| SCC | 201 (35.1%) | 44 (31.0%) | |
| No pathology | 6 (1.0%) | 4 (1.4%) | |
| Tumor location | 0.516 | ||
| Central | 88 (15.4%) | 25 (17.6%) | |
| Peripheral | 484 (84.6%) | 117 (82.4%) | |
| Tumor SUVmax | 0.227 | ||
| Median (Range) | 5.9 (0.0-45.0) | 5.0 (0.0-31.2) | |
| Treatment Characteristics | |||
| SABR prescription (Gy/fraction) | 0.910 | ||
| 50 Gy / 4 fractions | 444 (77.6%) | 111 (78.2%) | |
| 70 Gy / 10 fractions | 82 (14.3%) | 22 (15.5%) | |
| 54 Gy / 3 fractions | 21 (3.7%) | 4 (2.8%) | |
| Other | 25 (4.4%) | 5 (3.5%) | |
| PTV D95 BED10 (Gy) | 0.194 | ||
| Median (Range) | 113.3 (46.7-199.1) | 112.9 (53.3-150.1) | |
| PTVmean BED10 (Gy) | 0.148 | ||
| Median (Range) | 132.8 (64.6-236.2) | 132.6 (80.4-216.8) | |
Abbreviations: ECOG = Eastern Cooperative Oncology Group; CCI = Charlson comorbidity index; FEV1 = forced expiratory volume in 1 second; DLCO = diffusing capacity of carbon monoxide; NLR = neutrophil-to-lymphocyte ratio; SABR = stereotactic ablative radiotherapy; PLR = platelet-to-lymphocyte ratio; SII = systemic immune-inflammation index; SCC = squamous cell carcinoma; SUVmax = maximum standard uptake value of 18F-fluorodeoxyglucose positron emission tomography scan; PTVmean BED10 = mean biological equivalent dose to planning target volume; PTV D95 BED10 = minimum biological equivalent dose to 95% of planning target volume.